文献速递腹部CT

临界可切除胰腺癌术前MDCT可切除性评估:新辅助放化疗的影响

Preoperative MDCT Assessment of Resectability in Borderline Resectable Pancreatic Cancer: Effect of Neoadjuvant Chemoradiation Therapy.
PubMed 文献 · AJR Am J Roentgenol · 2018-02-28

本研究将37例临界可切除胰腺癌患者随机分入新辅助放化疗组(18例)或直接手术组(19例),由3名放射科医师用5分法在术前MDCT上评估局部可切除性,比较两组及不同阅片标准的诊断效能。结果显示新辅助放化疗未显著降低MDCT预测局部可切除性的效能,但结合放化疗后肿瘤-血管接触无进展等变化的新标准可能提高对局部可切除病变的敏感度。

要点

  • 临界可切除胰腺癌新辅助放化疗后,MDCT预测局部可切除性的AUC与直接手术组无显著差异。
  • 采用反映放化疗后变化的新标准后,新辅助放化疗组MDCT敏感度由22%升至78%,特异度由100%降至67%。
  • 评估新辅助放化疗后局部可切除性时,可关注肿瘤-血管接触无进展等变化。

核心结论

  • 在临界可切除胰腺癌患者中,新辅助放化疗未显著降低MDCT预测局部可切除性的效能。
  • 通过考虑放化疗后变化(如肿瘤-血管接触无进展),MDCT可能对局部可切除病变提供更好的敏感度。

研究设计与样本

  • 随机对照研究,37例临界可切除胰腺癌患者随机分入新辅助放化疗组(第1组,n=18)或直接手术组(第2组,n=19)。
  • 3名放射科医师在术前MDCT上以5分法评估局部可切除可能性,分两次独立阅片:第1次为新辅助放化疗组放化疗后与直接手术组基线,第2次采用反映放化疗期间变化的新影像标准。
  • 以手术结果为参考标准,比较两组及各次阅片的AUC、敏感度、特异度和准确率。

诊断标准与关键数值

  • 局部可切除性评估共30例;第1次阅片AUC:阅片者1为0.664、阅片者2为0.669、阅片者3为0.588。
  • 第1次阅片AUC:新辅助放化疗组(n=15)分别为0.759、0.713、0.593,直接手术组(n=15)分别为0.852、0.685、0.722,两组间差异无统计学意义(p>0.05)。
  • 新辅助放化疗组第1次阅片敏感度22%、特异度100%、准确率53%,第2次阅片敏感度78%、特异度67%、准确率73%(p>0.05)。

临床应用与阅片要点

  • 评估临界可切除胰腺癌新辅助放化疗后的局部可切除性时,可结合肿瘤-血管接触无进展等放化疗后变化进行判断。
  • 采用反映放化疗后变化的新影像标准,可能提高对局部可切除病变的敏感度,但特异度可能降低。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

OBJECTIVE: The purpose of this study is to evaluate the diagnostic performance of MDCT in assessing tumor resectability in patients with borderline resectable pancreatic cancers after receiving neoadjuvant chemoradiation therapy (CRT) in comparison with those undergoing upfront surgery.

SUBJECTS AND METHODS: Thirty-seven patients with borderline resectable pancreatic cancers were randomly allocated to the neoadjuvant CRT group (arm 1; n = 18) or up-front surgery group (arm 2; n = 19). Three radiologists rated the likelihood of local resectability on a 5-point scale at preoperative MDCT in two separate sessions (session 1: post-CRT of arm 1, baseline of arm 2; session 2: using new imaging criteria reflecting the changes during CRT of arm 1). The AUC of each reviewer, as well as sensitivity, specificity, and accuracy based on consensus interpretation, were compared between arms and sessions.

RESULTS: For local resectability (n = 30), AUC values at session 1 were 0.664, 0.669, and 0.588 for reviewers 1, 2, and 3, respectively, and were not significantly different between arms 1 (n = 15; 0.759, 0.713, and 0.593) and 2 (n = 15; 0.852, 0.685, and 0.722) (p > 0.05). In arm 1, MDCT sensitivity, specificity, accuracy were 22%, 100%, and 53%, respectively, at session 1 versus 78%, 67%, and 73%, respectively, at session 2 (p > 0.05).

CONCLUSION: In patients with borderline resectable pancreatic cancers, neoadjuvant CRT did not significantly decrease the performance of MDCT for the prediction of local resectability. However, by considering post-CRT changes, such as nonprogression in tumor-vascular contact, MDCT may provide better sensitivity for locally resectable disease.

来源:AJR Am J Roentgenol,查看原文。版权归原作者所有。

引用

  1. Joo I, Lee JM, Lee ES, et al. Preoperative MDCT Assessment of Resectability in Borderline Resectable Pancreatic Cancer: Effect of Neoadjuvant Chemoradiation Therapy. AJR Am J Roentgenol. 2018. PMID: 29489408. doi:10.2214/AJR.17.18310

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。